Sb. Bordow et al., PROGNOSTIC-SIGNIFICANCE OF MYCN ONCOGENE EXPRESSION IN CHILDHOOD NEUROBLASTOMA, Journal of clinical oncology, 16(10), 1998, pp. 3286-3294
Purpose: To assess the significance of MYCN gene expression as a progn
ostic factor in patients with neuroblastoma of various ages, and to de
termine whether it can predict for outcome independently of MYCN gene
amplification. Patients and Methods: The level of MYCN gene expression
in 60 specimens of primary untreated neuroblastoma was determined by
reverse-transcriptase polymerase chain reaction (RT-PCR) analysis, Res
ults: High levels of MYCN gene expression were associated with advance
d tumor stage (P =.0005), with the presence of MYCN gene amplification
(P <.000l), but not with older age at diagnosis. Among patients who l
acked MYCN gene amplification, the levels of MYCN gene expression were
significantly greater in the tumors of infants compared with those of
older children (P <.0005), High MYCN expression was strongly associat
ed with reduced survival and event-free survival in the overall study
population (P <.005), and also in the subset of patients aged older th
an 1 year at diagnosis (P <.001), In contrast, MYCN expression did not
appear to be predictive of outcome in infants. After adjustment for t
he effect of MYCN amplification, high levels of MYCN expression retain
ed significant prognostic value for poor survival (relative hazards, 3
0.3; P =.003) in children aged older than 12 months at diagnosis, Conc
lusion: High MYCN gene expression is strongly predictive of poor outco
me in older children with neuroblastoma, but not in infants. The findi
ngs help explain the controversy in the literature about the prognosti
c value of MYCN gene expression a nd high light the different biology
of neuroblastoma that presents in infants and older children. (C) 1998
by American Society of Clinical Oncology.